Prometheus

Prometheus is aninnovative medtech startup founded in 2017, which creates solutions for regenerative medicine and aims to integrate advanced technologies in the treatment of difficult-toheal skin wounds, such as pressure sores and diabetic ulcers.

From Prometheus comes Ematik: a personalised, bioresorbable plaster that combines the patient's blood with special biomaterials for the treatment of difficult wounds. The patch halves wound healing time by stimulating regeneration, without scar formation.

20 Million patients have a chronic wound, and every 30 seconds a limb is amputated due to lack of products that stimulate fast and effective regeneration. This forces patients to undergo frequent and painful treatments, which are often inconclusive. The products available today are ineffective.
The market for wound care products is worth €20 billion, with an annual growth rate of advanced products of 25%, indicating that advanced therapies will increasingly replace the use of traditional products.

Ematik has alreadydemonstrated its effectiveness on numerous animal clinical cases, in fact, it is already on the veterinary market since February 2020 for the treatment of wounds in dogs, cats and horses. The technology is also covered by 3 patents, which will be extended worldwide.

The team is extremely motivated, supported by an advisory board of excellence that includes Dr. Andrea Chies i of Chiesi farmaceutici (2nd most important Italian multinational pharmaceutical company); his value has also been recognized by the Seal of Excellence of the European Commission.
From a clinical point of view, the project is also supported by wound care luminaries, such as Dr. Lorenz Larcher of the Sant'Anna Clinic in Merano and Dr. Longobardi of the Hyperbaric Institute in Ravenna.

Thanks to your contribution, it will be possible to certify Ematik for human use and start today the regenerative medicine of the future.

On the campaign of Prometheus Srl is mandatory the Massive Rubrication Service for all membership amounts lower than 29.995,14€. The service is offered at no additional cost to the investor.